BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Swift Biosciences Release: New Primers Provide Significant Breakthrough in Assay Sensitivity


9/17/2012 12:22:20 PM

Ann Arbor, MI – September 17, 2012 - Swift Biosciences, Inc. has announced a new addition to its line of myT® Primer reagents for the detection of key cancer mutations. myT BRAF-Ultra, an ultrasensitive version of myT BRAF, provides 0.01% sensitivity down to single copy detection of BRAF mutations and is now available from Swift. myT BRAF-Ultra can detect less than 10 copies of mutant BRAF V600E/K with very low breakthrough amplification from a background of 10,000 wild-type genomic DNA copies. While myT BRAF-Ultra works well with fresh frozen and FFPE samples, this level of sensitivity also makes the product ideal for use when the sample material is limiting or where the target is present at very low concentration, such as with circulating tumor cells (CTCs), serum, plasma and needle biopsies. Each myT BRAF-Ultra package includes sufficient reagents to assess up to 14 samples when run in triplicate, plus a positive and a negative control.

myT BRAF-Ultra is the newest addition to the myT Primer line of products. The first product in the family, myT BRAF, can detect 1% mutant BRAF V600E/K present in a background of 1,000 wild-type genomic DNA copies with no breakthrough amplification from wild-type, resulting in assays that give definitive Yes/No answers over a wide dynamic range and reduce or completely eliminate the need for delta Ct methods to call results. Each myT BRAF package includes sufficient reagents to assess up to 28 samples plus a positive and a negative control.

The extreme selectivity and reproducibility of myT Primers provides an increased level of confidence and convenience in qPCR assays and makes them ideal for use when the sample material is limiting or where the target is present at very low concentration. Additional myT Primer reagents will be coming soon, including primers for high sensitivity detection of KRAS mutations in codons 12 and 13.

To learn more about the power of myT BRAF-Ultra or how myT Primers can improve your assay, please visit www.swiftbiosci.com.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES